2-deoxy-2-((18)F)fluoro-beta-D-glucose and Neoplasms

We describe the synthesis of (11)C-labeled α-aminoisobutyric acid 2 from iodo[(11)C]methane and methyl N-(diphenylmethylen)-d,l-alaniate (5). The tetrabutylammonium fluoride (TBAF)-promoted α-[(11)C]methylation of sterically hindered analog 5 was a key step in our synthesis process. Total radiochemical conversion of 2 was high and a remote-controlled synthesis was carried out. A comparative tumor positron emission tomography (PET) imaging study using the same model mouse showed higher uptake of 2 than with (11)C-labeled methionine and [(18)F] fluorodeoxyglucose (FDG).

Topics: Aminoisobutyric Acids; Animals; Carbon Radioisotopes; Disease Models, Animal; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals

This article reported the synthesis and bioevaluation of two [(18)F] labeled benzimidazole derivatives, 4-(5-(2-[(18)F] fluoro-4-nitrobenzamido)-1-methyl-1H-benzimidazol-2-yl) butanoic acid ([(18)F] FNBMBBA, [(18)F]a1) and 3-(2-fluoroethyl)-7-methyl-2-propyl-3H-benzimidazole-5-carboxylic acid ([(18)F] FEMPBBA, [(18)F]b1) for PET tumor imaging. The preparation [(18)F] FEMPBBA was completed in 1h with overall radiochemical yield of 50-60% (without decay corrected). Biodistribution assay in S180 tumor bearing mice of both compounds were carried out, and the results are both meaningful. [(18)F] FEMPBBA which can be taken as a revision of [(18)F] FNBMBBA got an excellent result, and has significant advantages in some aspects compared with L-[(18)F] FET and [(18)F]-FDG in the same animal model, especially in tumor/brain uptake ratio. The tumor/brain uptake ratio of [(18)F] FEMPBBA gets to 4.81, 7.15, and 9.8 at 30min, 60min and 120min, and is much higher than that of L-[(18)F] FET (2.54, 2.92 and 2.95) and [(18)F]-FDG (0.61, 1.02, 1.33) at the same time point. The tumor/muscle and tumor/blood uptake ratio of [(18)F] FEMPBBA is also higher than that of L-[(18)F] FET at 30min and 60min. This result indicates compound [(18)F] FEMPBBA is a promising radiotracer for PET tumor imaging.

Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Benzimidazoles; Chromatography, High Pressure Liquid; Female; Fluorine Radioisotopes; Indicators and Reagents; Isotope Labeling; Mice; Neoplasms; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma 180; Solubility; Solvents; Tissue Distribution

Two F-18 labeled fluoroarylvaline derivatives, methyl 2-(2-[(18)F]fluoro-4-nitrobenzamido)-3-methylbutanoate ([(18)F]1, [(18)F]MFNBMB) and its corresponding acid 2-(2-[(18)F]fluoro-4-nitrobenzamido)-3-methylbutanoic acid ([(18)F]2, [(18)F]FNBMBA), have been designed and synthesized, respectively, by our team. Meanwhile, we research on their biodistributions in mice model bearing S 180 tumor. Furthermore, we also carried out the biological evaluations of 2-[(18)F]fluorodeoxyglucose ([(18)F]FDG) and O-2-[(18)F]fluoroethyl-l-tyrosine (l-[(18)F]FET) in the same model for comparison with our targeting molecules [(18)F]1 and [(18)F]2. Excitingly, the tumor/blood (T/Bl) and tumor/brain (T/Br) ratios were 2.91, 7.06 at 30 min, 3.44, 5.61 at 60 min post injection for [(18)F]1, 2.32, 13.30 for [(18)F]2 at 30 min post injection, which were obviously superior to [(18)F]FDG and l-[(18)F]FET in the same model and demonstrated that [(18)F]1 and [(18)F]2, especially [(18)F]2, were potential PET imaging agents for tumor detection.

Topics: Animals; Benzamides; Butyrates; Cell Line, Tumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tyrosine